Topline olezarsen data from the Phase 3 CORE and CORE2 trials in patients with severe hypertriglyceridaemia (sHTG) show significant placebo-adjusted mean reductions in fasting TG of up to 72% at six months, and a pre-specified analysis of pooled data from olezarsen and placebo groups in both studies show a statistically significant reduction in acute pancreatitis events of 85% (p=0.0002) at 12 months.
New clues to link between postprandial plasma TG and CV and T2D risk
Biochemical and genomic results from a study of 21 healthy, non-obese individuals aged 18-40 years have shown that those with high post-prandial TG (HPTG) five hours after a high fat meal had significantly higher levels of plasma insulin and lipopolysaccharide-binding protein (LPB) than those with low post-prandial TG (LPTG), potentially putting them at higher risk of cardiovascular disease (CVD) and type 2 diabetes (T2D).
Maastricht Study shows increased HTG risk with steatotic liver disease
Genetically predisposed individuals have a substantially higher risk of hypertriglyceridaemia when they also have steatotic liver disease, according to results from the Maastricht Study, a population-based, prospective cohort analysis.
Topline Essence-TIMI 73b data support olezarsen in moderate hypertriglyceridaemia
Topline results from the Phase 3 Essence-TIMI 73b study provide encouraging evidence of the efficacy of olezarsen in patients with moderate hypertriglyceridaemia (fasting TG 150 mg/dL to <500 mg/dL) with or at risk of atherosclerotic cardiovascular disease (ASCVD).
Preclinical data support MAR001 safety and therapeutic potential
Results of preclinical studies with the ANGPTL4 antibody, MAR001, support its therapeutic potential and help allay safety concerns about ANGPTL4 inhibition. The results, published in eBioMedicine, show that, in cynomolgus monkeys with hypertriglyceridaemia, a single dose of MAR001 3 mg/kg sc reduced plasma TG by more than 40% from baseline within three days of dosing and led to a peak TG reduction of 58% on day 7 post-dose. MAR001 consistently lowered plasma TG by more than 40% from baseline on days 3 through 21 post-dose. There were also reductions in non-HDL-C, apoB and remnant cholesterol (RC) of 38%, 30%, and 59% respectively.
Hypertriglyceridaemia still common in CHD secondary prevention patients
One in three individuals receiving CHD secondary prevention care has hypertriglyceridaemia (HTG), despite the fact that 85% use lipid-modifying therapies, mainly statins.
